Scoop: Infectious disease biotech eyes $25M Series A to advance antibody for chronic lung infection
Infex Therapeutics is planning to raise up to £20 million ($25 million) in a Series A round with an eye to progressing its lead asset — which it in-licensed from Japanese pharma Shionogi — through to Phase IIb in chronic Pseudomonas aeruginosa infection in people with non-cystic fibrosis bronchiectasis (NCFB).
“We’re looking to build a book of investors through the end of quarter one [in 2024] and into quarter two,” executive director Peter Jackson told Endpoints News in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.